Lizhu Lin

机构：Guangzhou University of Chinese Medicine, First Affiliated Hospital of Guangzhou University of Chinese Medicine, Chi Mei Medical Center · ORCID：0000-0001-8283-6554

发表论文 104 篇 · 总被引 2368 次 · h-index 23

代表论文

• Camrelizumab Plus Carboplatin and Pemetrexed as First-Line Treatment for Advanced Nonsquamous NSCLC: Extended Follow-Up of CameL Phase 3 Trial (2023 · Journal of Thoracic Oncology · 被引 72)
• Negative association of C-reactive protein-albumin-lymphocyte index (CALLY index) with all-cause and cause-specific mortality in patients with cancer: results from NHANES 1999–2018 (2024 · BMC Cancer · 被引 52)
• Database mining and animal experiment-based validation of the efficacy and mechanism of Radix Astragali (Huangqi) and Rhizoma Atractylodis Macrocephalae (Baizhu) as core drugs of Traditional Chinese medicine in cancer-related fatigue (2021 · Journal of Ethnopharmacology · 被引 38)
• Camrelizumab plus carboplatin and pemetrexed as first-line therapy for advanced non-squamous non-small-cell lung cancer: 5-year outcomes of the CameL randomized phase 3 study (2024 · Journal for ImmunoTherapy of Cancer · 被引 26)
• Yifei sanjie Pills Alleviate Chemotherapy-Related Fatigue by Reducing Skeletal Muscle Injury and Inhibiting Tumor Growth in Lung Cancer Mice (2022 · Evidence-based Complementary and Alternative Medicine · 被引 19)
• Expert consensus on treatment for stage III non‐small cell lung cancer (2023 · Medicine Advances · 被引 18)